arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Telomir Pharmaceuticals, Inc.

TELO

$1.16 ▼ -0.02 (-1.69%) at close

15 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Telomir Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $39.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC None

FCF / Share $-0.05

Trailing P/E —

Price / Book 8.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-990.95K

↑ +54.5% —

FCF / Share Free cash flow per share

$-0.05

↓ -77.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	57.1% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	40.0% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	85.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	69.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	-233.3% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	16.7% Good Good Year-over-year change in earnings per share Optimal: > 10%	-1050.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	54.5% Excellent ↑ Excellent Improving Year-over-year change in net income	28.9% Excellent ↑ Excellent Improving Year-over-year change in net income	63.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-50.4% Weak ↓ Weak Declining Year-over-year change in net income	65.1% Excellent ↑ Excellent Improving Year-over-year change in net income	68.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-250.1% Weak ↑ Weak Improving Year-over-year change in net income	6.5% Fair Fair Year-over-year change in net income	-1195.1% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-77.9% Weak Weak Year-over-year change in free cash flow	—	—	—	58.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-155.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
FCF / Net Income (x)	1.79x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.21x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.31x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.12x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.02x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.52x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	—	—	—	—	-1072.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
Return on Capital (%) (%)	—	—	—	—	445.4% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
Return on Common Equity (%) (%)	-20.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-233%)	-34.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-332%)	-31.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-308%)	—	—	—	—	-92.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-716%)	-207.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1482%)	-271.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1909%)	-78.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-624%)	-39.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-366%)	94.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+531%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	—	—	—	$-754.32K	$-403.00K	—	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-0.03	$-0.06	$-0.03	$0.17	$-0.07	$-0.10	$-0.20	$-0.05	$-0.23	$0.62	$-0.06	$-0.06	$-0.02	—	—
Free Cash Flow per Share (USD)	$-0.05	—	$-0.03	$-0.02	$-0.03	—	—	—	$-0.07	—	$-0.07	$-0.00	$-0.03	—	—
Book Value per Share (USD)	$0.14	$0.17	$0.21	$0.02	$-0.01	$0.02	$0.01	$0.05	$0.10	$0.12	$0.08	$0.14	$-0.02	$-0.03	—
Tangible Book Value per Share (USD)	$0.14	$0.17	$0.21	$0.02	$-0.01	$0.02	$0.01	$0.05	$0.10	$0.12	$0.08	$0.14	$-0.02	$-0.03	—
Basic Weighted Avg Shares (shares)	34.38M	—	32.40M	30.01M	29.76M	—	29.61M	29.61M	27.77M	—	27.10M	27.10M	26.89M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$4.96M	$5.91M	$6.98M	$481.22K	$-161.11K	$643.04K	$442.07K	$1.57M	$3.02M	$-900.34K	—	—	—	$-937.28K	—
Total Equity (USD)	$4.96M	$5.91M	$6.98M	$481.22K	$-161.11K	$643.04K	$442.07K	$1.57M	$3.02M	$3.44M	$2.18M	$3.89M	$-510.22K	$-937.28K	$-138.13K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Net Income, GAAP (USD)	$-990.95K	$-2.06M	$-2.18M	$-2.18M	$-2.18M	$-2.90M	$-5.99M	$-1.45M	$-6.25M	$-9.33M	$-1.71M	$-1.55M	$-482.94K	—	—
Operating Cash Flow (USD)	$-1.77M	$-1.20M	$-927.26K	$-696.45K	$-863.13K	$-605.81K	—	—	$-1.94M	$-1.09M	$-2.00M	$-33.58K	$-735.74K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 15 quarters

Telomir Pharmaceuticals, Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TELO with peers